Platelet aggregation induced by antilymphocyte serum. I. Differences between washed and unwashed platelets

Area of Science:

• Immunology
• Hematology
• Cell Biology

Background:

• Antilymphocyte serum (ALS) is used therapeutically but can have side effects.
• Platelets play a crucial role in hemostasis and immune responses.
• Understanding ALS-platelet interactions is vital for clinical safety.

Purpose of the Study:

• To investigate the effects of horse antilymphocyte serum (ALS) on human platelets.
• To elucidate the mechanisms underlying ALS-induced platelet aggregation and lysis.
• To differentiate the effects of ALS on washed versus unwashed human platelets.

Main Methods:

• Human platelet aggregation assays.
• Nucleotide release measurements.
• Platelet lysis studies.
• Electron microscopy for ultrastructural analysis.
• Inhibition studies using heparin and prostaglandin E1 (PGE1).

Main Results:

• ALS induced nucleotide release and aggregation in washed human platelets.
• ALS caused platelet lysis in plasma.
• ALS-induced aggregation was independent of ADP but sensitive to secondary aggregation inhibitors.
• Heparin inhibited ALS effects on unwashed platelets, while PGE1 inhibited washed platelets.
• PGE1 inhibited aggregation and nucleotide release in washed platelets.

Conclusions:

• ALS triggers distinct platelet responses depending on the presence of plasma.
• Mechanisms of ALS-induced platelet aggregation and lysis differ between washed and unwashed platelets.
• Specific inhibitors highlight differential pathways involved in ALS-mediated platelet activation and damage.